Immunological Responses and Survival Outcome in HIV and SARS-CoV-2 Coinfected Patients

Uzma A. Jilani^1*, Zulhabri Othman², Syed A. Jilani³

Abstract

The coronavirus disease 2019 (COVID‐19) has created a worldwide crisis, raising fears and concerns regarding clinical outcomes in patients with comorbidities. Some of the highly prevalent communicable and non-communicable diseases worldwide are cardiovascular diseases, diabetes, HIV/AIDS, and hepatitis B and C, which reduce the host immune responses to concurrent acute infections. Despite over 170 million confirmed cases of COVID‐19 worldwide as of 24 June 2021, insufficient data is reporting the prognosis of HIV and SARS-CoV-2 co‐infection. This narrative review aims to present current knowledge on the impact of SARS-CoV-2 on people living with HIV/AIDS, in terms of immunological responses and clinical outcome. Although some studies have been performed and are in progress to determine the impact of SARS-CoV-2 infection on patients living with HIV/AIDS, controversies still exist whether COVID-19 severity and mortality are higher among this special subgroup or similar to the general population.

Keywords

SARS-CoV-2 and HIV co-infection; COVID-19 mortality; immunological response to HIV; immunological response to SARS-CoV-2; HIV/SARS-CoV-2 co-infection survival

Cite This Article

Jilani, U. A., Othman, Z., Jilani, S. A. (2021). Immunological Responses and Survival Outcome in HIV and SARS-CoV-2 Coinfected Patients. International Journal of Scientific Advances (IJSCIA), Special Issue: Sep 2021, Pages 26-32, URL: https://www.ijscia.com/wp-content/uploads/2021/09/Special-Issue-No.04-26-32.pdf

Publication In

Special Issue 2: Sep 2021 

COVID-19 PANDEMIC: BEFORE & AFTER